Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report
Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19...
Guardado en:
Autores principales: | Daniel Nan, Cristina Abraira-Meriel, Sandra de la Roz-Fernandez, Tamara Maestre-Orozco, Jose Luis Hernandez, Marta Fernandez-Ayala |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SMC MEDIA SRL
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2c88b730844e40fd9fd30026631acb45 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Defective Glyoxalase 1 Contributes to Pathogenic Inflammation in Cystic Fibrosis
por: Marilena Pariano, et al.
Publicado: (2021) -
An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
por: Bullement A, et al.
Publicado: (2021) -
Woronoff Ring in Deficiency of Interleukin-36 Receptor Antagonist (DITRA)
por: Daniel Morgado-Carasco, et al.
Publicado: (2019) -
Fibrosis pulmonar aguda asociada a intoxicación por Paraquat: caso clínico
por: Cartagena,Sebastián, et al.
Publicado: (2018) -
Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials
por: Dimitrios Sagris, et al.
Publicado: (2021)